title: Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators.
abstract: BACKGROUND
  Little information exists concerning practice patterns between Canada and the United States in the management of myocardial infarction (MI) patients without ST-segment elevation and unstable angina.
  
  
  RESULTS
  We examined the practice patterns and 1-year outcomes of 2250 US and 922 Canadian patients without ST-elevation acute coronary syndromes in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb trial. The US hospitals more commonly had on-site facilities for angiography and revascularization. These procedures were performed more often and sooner in the United States than Canada, whereas Canadian patients were more likely to undergo noninvasive stress testing. The length of initial hospital stay was 1 day longer for Canadian than US patients. Recurrent and refractory ischemia was more common in Canada. One-year mortality was comparable between the 2 countries. However, at 6 months, even after baseline differences were accounted for, the (re)MI rate was significantly higher in Canadian than US patients with unstable angina (8.8% versus 5.8%, P:=0.039), as was the composite rate of death or (re)MI (13.1% versus 9.1%, P:=0.016).
  
  
  CONCLUSIONS
  One-year mortality was comparable between Canada and the United States in both MI and unstable angina cohorts despite higher intervention rates in the United States. However, outcomes at 6 months among patients with unstable angina differed. Whereas more frequent coronary interventions were not associated with reduced recurrent MI or death among MI patients without ST elevation, they may favorably affect outcomes in patients with unstable angina.
authors.affiliation: University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Y
authors.initials: Y
authors.lastname: Fu
authors.forename: W C
authors.initials: WC
authors.lastname: Chang
authors.forename: D
authors.initials: D
authors.lastname: Mark
authors.forename: R M
authors.initials: RM
authors.lastname: Califf
authors.forename: B
authors.initials: B
authors.lastname: Mackenzie
authors.forename: C B
authors.initials: CB
authors.lastname: Granger
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
authors.forename: M
authors.initials: M
authors.lastname: Hlatky
authors.forename: P W
authors.initials: PW
authors.lastname: Armstrong
mesh_terms: D000704:Analysis of Variance; D000789:Angina, Unstable / Q000401:mortality / Q000628:therapy*; D002170:Canada; D003325:Coronary Care Units / Q000706:statistics & numerical data; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D024764:Hirudin Therapy; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D010818:Practice Patterns, Physicians'; D012044:Regression Analysis; D016896:Treatment Outcome; D014481:United States
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin